Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarina A
SA
Piha-Paul
David S
DS
Hong
Razelle
R
Kurzrock
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001706:Biopsy; D005260:Female; D006801:Humans; D018192:Lymphangioleiomyomatosis / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D012186:Retroperitoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab; C401859:temsirolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus